XML 17 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)
In Thousands, except Share data, unless otherwise specified
 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]    
Revenues $ 184   
Cost of revenues 234   
Gross loss (50)   
Operating expenses:    
Research and development expenses, net 6,176 4,047
Marketing and business development expenses 352 351
General and administrative expenses 2,105 1,679
Total operating expenses 8,633 6,077
Operating loss (8,683) (6,077)
Financial income, net 2,270 1,332
Net loss (6,413) (4,745)
Unrealized gain arising during the period on Investment in Evogene 924 569
Realized gain (loss) arising during the period on Investment in Evogene (1,453)   
Total comprehensive loss $ (6,942) $ (4,176)
Basic net loss per share $ (0.17) $ (0.13)
Weighted average number of Ordinary shares used in computing basic net loss per share 37,746,520 35,628,390
Diluted net loss per share $ (0.18) $ (0.13)
Weighted average number of Ordinary shares used in computing diluted net loss per share 39,140,651 35,628,390